TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Highly active RMS as defined by:~* One relapse in the previous year and at least 1 T1 Gadolinium (Gd)+ lesion or 9 or more T2 lesions, while on therapy with other disease modifying drugs (DMDs)~* Two or more relapses in the previous year, whether on DMD treatment or not.~* Expanded Disability Status Scale (EDSS) score less than equals to (\<=) 5.0.~* Other protocol defined inclusion criteria could apply.~Exclusion Criteria:~* Previous exposure to drugs such as fingolimod, natalizumab, alemtuzumab, mitoxantrone and ocrelizumab.~* Positive hepatitis C or hepatitis B surface antigen test and/or hepatits B core antibody test for immunoglobulin G (IgG) and/or immunoglobulin M (IgM).~* Current or previous history of immune deficiency disorders including a positive human immunodeficiency virus (HIV) result.~* Currently receiving immunosuppressive or myelosuppressive therapy with, for example, monoclonal antibodies, methotrexate, cyclophosphamide, cyclosporine or azathioprine, or chronic use of corticosteroids.~* History of tuberculosis , presence of active tuberculosis, or latent tuberculosis~* Evidence or suspect of Progressive Multifocal Leukoencephalopathy (PML) in Magnetic Resonance Imaging (MRI).~* Active malignancy or history of malignancy.~* Other protocol defined exclusion criteria could apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mavenclad® (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetics of Alcohol: Treatment Implications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Main Study: Subjects will be healthy volunteers with or without parental history of alcoholism who are 21-45 years old and who have a BMI \>18.5 and \<32.5. Drinking history: All subjects must report at least one occasion in the prior month of drinking at least 3 drinks on a single day; additionally, LD subjects will be selected if they drink 1-3 drinks, 1-3 times per week (up to 5 drinks per week on average), with no more than one occasion in the past 2 months on which they drank \>4 drinks. HD subjects will be selected if they report drinking at least 10 drinks per week, with at least one episode per week of heavy drinking.~Exclusion Criteria:~* Main Study: Subjects cannot have a current or past DSM-IV diagnosis of alcohol or drug dependence, current or past 24-months diagnosis of alcohol or drug abuse or another major psychiatric disorder, neurological illness, have had a hypersensitivity reaction to dutasteride, evidence of liver dysfunction, currently be using benzodiazepines, other psychotropic medications or medications that are known to influence steroid hormone levels or metabolism or modify the effects of alcohol. Nicotine-dependent subjects will be excluded to avoid the confounding effects of nicotine withdrawal during day-long laboratory sessions. Women are not allowed to participate. Subjects anticipating moving from the area during the period of their planned study participation will be excluded from study entry.

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Placebo medication + placebo alcohol (Type: PLACEBO_COMPARATOR): None
- Placebo Medication + 0.8 gr/kg Ethanol (Type: EXPERIMENTAL): None
- 4 mg Dutasteride + Placebo Alcohol (Type: EXPERIMENTAL): None
- 4 mg Dutasteride + 0.8 gr/kg Ethanol (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with normal hepatic function or hepatic impairment (mild, moderate or severe)~* Body mass index (BMI) 18.5-40.0 kg/m\^2 (both inclusive)~Exclusion Criteria:~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods~* History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease~* Uncontrolled hypertension (defined as systolic blood pressure above or equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)~* Any donation of blood or plasma in excess of 400 mL within the 3 months preceding screening~* History of significant drug abuse, or a positive drug test at the screening visit (Visit 2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Subjects with hepatic impairment (Type: EXPERIMENTAL): None
- Subjects with normal hepatic function (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vistakon Investigational Lens Worn as a Single Use Daily Wear

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* eyes must be best-corrected to a visual acuity of 20/30 or better in each eye~* must be able and willing to wear soft contact lenses on a single use, daily wear basis for the duration of the study~* distance spherical contact lens prescription must be within the range available for the study~Exclusion Criteria:~* systemic diseases which may interfere with contact lens wear~* ocular infection or clinically significant ocular disease~* any previous intraocular surgery~* grade 2 or greater slit lamp findings~* currently pregnant or lactating~* more than 1.00D of refractive astigmatism in either eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- narafilcon B (Type: EXPERIMENTAL): contact lens
- etafilcon A (Type: ACTIVE_COMPARATOR): contact lens

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with unresectable or metastatic stage III B/C or IV melanoma. Patients enrolled under this version of the protocol must also have progressed on prior anti-PD-1 therapy, according to RECIST 1.1 criteria. Patients who progressed within 3 months of treatment start are excluded.~2. Patients must have at least one cutaneous or subcutaneous tumor, measuring 0.5 to 5.0 cm in the longest diameter, or a palpable lymph node. At least one tumor must qualify as an index lesion that can be accurately and reproducibly measured in two dimensions for which the longest diameter is .10 mm (.15 mm in short axis diameter \[SAD\] for lymph nodes), and be amenable to intratumoral injection.~3. Histological confirmation of melanoma will be required by previous biopsy or cytology.~4. Patients who have received prior ipilimumab treatment for metastatic melanoma are not eligible.~5. Patients with ≤ 3 visceral metastases (excluding pulmonary lesions), with no lesions \>3.0 cm. Patients with substantial tumor burden of non-measurable disease may not be good candidates for an immunotherapy and should be discussed with the Medical Monitor.~7. ECOG performance status of 0-1.~Key Exclusion Criteria:~1. Patients with tumors to be injected lying close to an airway, major blood vessel or spinal cord that, in the opinion of the Investigator, could cause occlusion or compression in the case of tumor swelling or erosion into a major vessel in the case of necrosis. Patients with lesions in mucosal areas (vulvar, anus, oral cavity, etc.), are eligible, as long as the subject has at least one lesion suitable for injection; consult Medical Monitor for confirmation.~2. Patients with active, known or suspected autoimmune disease except for autoimmune thyroiditis or vitiligo. Thyroiditis patients must be asymptomatic, on adequate thyroid replacement and have normal thyroid function tests.~3. Patients with active colitis or immune-mediated colitis that has not resolved to grade 1 or less.~4. Patients with untreated brain metastases. Patients with treated brain metastases who are off corticosteroids for at least two weeks and who demonstrate control of brain metastases with follow-up imaging 4 or more weeks after initial therapy are eligible.~5. Patients previously treated with CVA21.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CAVATAK and ipilimumab (Type: EXPERIMENTAL): CAVATAK intratumoral injection up to a total dose of 3 x 10⁸ TCID50 and ipilimumab intravenously at the recommended dose of 3 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 years or older who has been hospitalised for chest pain and potential ACS~* Females of child-bearing potential must have a negative pregnancy test at enrollment and be willing to use 2 methods of reliable contraception~Exclusion Criteria:~* Persons with moderate or severe liver disease~* Persons who have already been treated with an invasive (angioplasty) procedure for the current episode of ACS~* Persons who are being treated with blood clotting agents that cannot be stopped

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: ACTIVE_COMPARATOR): Oral treatment
- Ticagrelor (Type: EXPERIMENTAL): Oral treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Body dysmorphic disorder of at least moderate severity, non-delusional subtype, for \>6 months~* History of intolerance of, or nonresponse to, a prior adequate trial of a serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)~* Currently in psychotherapy (other than cognitive behavioral therapy (CBT) for body dysmorphic disorder~Exclusion Criteria:~* Current major depressive disorder of greater than moderate severity~* Other significant psychiatric or medical comorbidity or conditions that could interfere with safety of participation or interpretation of outcomes~* Use of: investigational medication within 3 months of baseline; depot antipsychotic within 6 months of baseline; serotonergic medication within 2 weeks of baseline (6 weeks for fluoxetine).~* Females who are pregnant, breastfeeding, or sexually active and not willing to use adequate contraception~* Enrollment in any investigational drug or device study in past 30 days~* Prior adverse effects from psilocybin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Psilocybin (Type: EXPERIMENTAL): A single dose of Psilocybin 25mg p.o.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Extended Gestational Age Medical Abortion Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* intrauterine pregnancy of greater than 56 days and less than 71 days~* eligible for medical abortion according to study doctor assessment~* willing and able to sign consent forms~* speak English or Spanish (in US sites); speak the local language(s) (in international sites)~* agree to comply with the study procedures and visit schedule

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 64-70 days' gestational age (Type: EXPERIMENTAL): Women whose pregnancies are estimated to have a gestational age of 64-70 days
- 57-63 days' gestational age (Type: NO_INTERVENTION): Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically proven breast cancer~* eligible for six cycles of neoadjuvant or adjuvant chemotherapy~Exclusion Criteria:~* concurrent or prior chemotherapy for breast cancer~* concurrent or prior anti-cancer treatment for breast cancer such as endocrine therapy, immunotherapy, monoclonal antibodies, and/or biological therapy~* concurrent prophylactic antibiotics~* previous therapy with any G-CSF (granulocyte-colony stimulating factor) product~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LA-EP2006 (Type: EXPERIMENTAL): During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.
- Neulasta® (Type: ACTIVE_COMPARATOR): During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Healthy Japanese male subjects~Exclusion criteria:~1. Any relevant deviation from healthy conditions

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Idarucizumab single doses (Type: EXPERIMENTAL): different infusion durations
- Idarucizumab with dabigatran (Type: EXPERIMENTAL): short infusion with 2 capsules dabigatran

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-Androgen Treatment for COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male age ≥18 years old~2. Laboratory confirmed positive SARS-CoV-2 rtPCR test within 7 days prior to randomization~3. Clinical status on the COVID-19 8-point Ordinal Scale of 1 or 2~4. Coagulation: INR ≤ 1.5×ULN, and APTT ≤ 1.5×ULN~5. Subject (or legally authorized representative) gives written informed consent prior to any study screening procedures~6. Subject (or legally authorized representative) agree that subject will not participate in another COVID-19 trial while participating in this study~Exclusion Criteria:~1. Subject enrolled in a study to investigate a treatment for COVID-19~2. Subject taking an anti-androgen of any type including: androgen depravation therapy, 5-alpha reductase inhibitors, etc...~3. Patients who are allergic to the investigational product or similar drugs (or any excipients);~4. Subjects who have malignant tumors in the past 5 years, with the exception of completed resected basal cell and squamous cell skin cancer and completely resected carcinoma in situ of any type~5. Subjects with known serious cardiovascular diseases, congenital long QT syndrome, torsade de pointes, myocardial infarction in the past 6 months, or arterial thrombosis, or unstable angina pectoris, or congestive heart failure which is classified as New York Heart Association (NYHA) class 3 or higher, or left ventricular ejection fraction (LVEF) \< 50%, QTcF \> 450 ms~6. Subjects with uncontrolled medical conditions that could compromise participation in the study(e.g. uncontrolled hypertension, hypothyroidism, diabetes mellitus)~7. Known diagnosis of human immunodeficiency virus(HIV) , hepatitis C, active hepatitis B, treponema pallidum (testing is not mandatory）~8. Alanine Transaminase (ALT) or Aspartate Transaminase (AST) \> 5 times the upper limit of normal.~9. Estimated glomerular filtration rate (eGFR) \< 30 ml/min~10. Severe kidney disease requiring dialysis~11. Subject unlikely to return for day 15 site visit for reasons other then remission~12. Subject (or legally authorized representative) not willing or unable to provide informed consent

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: ACTIVE_COMPARATOR): Usual care as determined by the PI
- Proxalutamide + Usual Care (Type: EXPERIMENTAL): Proxalutamide + Usual care as determined by the PI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: His Bundle Pacing Versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 18 years of age~* LV systolic dysfunction with LVEF ≤ 35%~* Evidence of intraventricular conduction delay with QRS duration \> 120 msec~* NYHA Class II, III, and ambulatory Class IV heart failure with either ischemic or nonischemic cardiomyopathy and patients with NYHA Class I symptoms and ischemic cardiomyopathy~* Left ventricular ejection fraction (LVEF) ≤ 35%, sinus rhythm (SR), left bundle-branch block (LBBB) morphology, and QRS duration ≥ 150 msec, and NYHA Class II, III, or ambulatory Class IV patients on goal-directed medical therapy (GDMT) \[Class I\]~* LVEF ≤ 35%, SR with LBBB with QRS 120-149 msec on GDMT \[Class IIa\]~* LVEF ≤ 35%, SR with non-LBBB with QRS ≥ 150 msec on GDMT \[Class IIa\]~* LVEF ≤ 35%, in AF if medication or AV nodal ablation will allow near 100% pacing \[Class IIa\]~* LVEF ≤ 35% undergoing new or replacement device with anticipated \>40% ventricular pacing on GDMT \[Class IIa\]~* LVEF ≤ 30%, ischemic etiology of HF, SR with LBBB ≥ 150 msec and NYHA Class I symptoms on GDMT \[Class IIb\]~* LVEF ≤ 35%, SR with non-LBBB with QRS 120-149 msec, NYHA Class III/ambulatory Class IV HF on GDMT \[Class IIb\] LVEF ≤ 35%, SR with non-LBBB with QRS ≥ 150 msec, NYHA Class II HF on GDMT \[Class IIb\]~Exclusion Criteria:~* Existing CRT device~* Inability of patient capacity to provide consent for themselves either due to medical or psychiatric comorbidity~* Pregnancy~* Participation in other trials~* Difficulty with follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- His Bundle Pacing (Type: ACTIVE_COMPARATOR): Subjects will be randomized to the HB lead position with their cardiac resynchronization therapy (CRT) pacemaker. HB lead pacing will be performed with the Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Both devices are FDA approved for the purpose of HB pacing. It is the only device available which is presently FDA approved for selective HB pacing.
- Coronary Sinus Pacing (Type: ACTIVE_COMPARATOR): Subjects will be randomized to the CS lead position with their cardiac resynchronization therapy (CRT) pacemaker. CS lead and CRT device generator selected for implant will be left to the discretion of the operator. Only FDA approved CS leads and CRT generators will be utilized in the study. There are five present manufacturers of CS leads and CRT generators: Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete